Loading patent…
OwnerKristen Pierce, Janine Powers +4inventors
InventorsKristen Pierce, Janine Powers, Servando Palencia, Robert Sikorski, Majid Ghoddusi, Kartik Krishnan
Estimating the term…
Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
A method of treating bladder cancer in a subject comprising administering to the subject a fibroblast growth factor receptor 2 (FGFR2) inhibitor and at least one programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor, wherein the FGFR2 inhibitor is an anti-FGFR2-IIIb antibody that binds to FGFR2-IIIb and does not detectably bind to FGFR4;
Dependencies are inferred from the claim text.